BRPI0604997A - vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção - Google Patents

vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção

Info

Publication number
BRPI0604997A
BRPI0604997A BRPI0604997-4A BRPI0604997A BRPI0604997A BR PI0604997 A BRPI0604997 A BR PI0604997A BR PI0604997 A BRPI0604997 A BR PI0604997A BR PI0604997 A BRPI0604997 A BR PI0604997A
Authority
BR
Brazil
Prior art keywords
lymphocytes
group
protein
obtaining
procedure
Prior art date
Application number
BRPI0604997-4A
Other languages
English (en)
Inventor
Luiza Guilherme Guglielmi
Jorge Elias Kalil Jr
Original Assignee
Fundacao Zerbini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Zerbini filed Critical Fundacao Zerbini
Priority to BRPI0604997-4A priority Critical patent/BRPI0604997A/pt
Publication of BRPI0604997A publication Critical patent/BRPI0604997A/pt
Priority to CN2007800438724A priority patent/CN101557822B/zh
Priority to KR1020097013570A priority patent/KR101511800B1/ko
Priority to JP2009538555A priority patent/JP5410294B2/ja
Priority to US12/516,754 priority patent/US8642049B2/en
Priority to PCT/BR2007/000184 priority patent/WO2008064440A1/en
Priority to EP20070784913 priority patent/EP2099481A4/en
Priority to US14/171,299 priority patent/US9289485B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

VACINA CONTRA O ESTREPTOCOCO BETA HEMOLìTICO DO GRUPO A, E RESPECTIVO PROCESSO DE OBTENçãO, que prevê a produção de proteína recombinante clonada a partir do gene emm5, que contém seqüência de oligonucleotídeos correspondente a 52 e/ou 87 resíduos de aminoácidos com capacidade de proteção, isolada após a identificação molecular seqüencial de epitopos da região carboxi-terminal da proteína M, diferindo em 01 resíduo de aminoácido, identificados por anticorpos e linfócitos T de seres humanos sadios e de pacientes portadores de febre reumática capazes de gerar resposta protetora por anticorpos dependentes de linfócitos T; a prevenção de desenvolvimento de doença auto-imune pelo epitopo selecionado foi avaliada in vitro com linfócitos T provenientes de tecido cardíaco de pacientes com lesões decorrentes da febre reumática.
BRPI0604997-4A 2006-11-30 2006-11-30 vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção BRPI0604997A (pt)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0604997-4A BRPI0604997A (pt) 2006-11-30 2006-11-30 vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção
CN2007800438724A CN101557822B (zh) 2006-11-30 2007-07-19 抵抗A组β溶血性链球菌的疫苗及其制备工艺
KR1020097013570A KR101511800B1 (ko) 2006-11-30 2007-07-19 Ａ군 베타 용혈성 스트렙토코커스에 대한 백신 및 이의 수득 방법
JP2009538555A JP5410294B2 (ja) 2006-11-30 2007-07-19 Ａ型β溶血性連鎖球菌に対するワクチン及びその取得方法
US12/516,754 US8642049B2 (en) 2006-11-30 2007-07-19 Vaccine against group A beta hemolytic streptococcus and respective process for obtaining thereof
PCT/BR2007/000184 WO2008064440A1 (en) 2006-11-30 2007-07-19 Vaccin against group a beta hemolytic streptococcus and respective process for obtaining thereof
EP20070784913 EP2099481A4 (en) 2006-11-30 2007-07-19 VACCINATE AGAINST GROUP A BETA-HEMOLYTIC STREPTOCOCCUS AND RELEVANT METHOD FOR OBTAINING THE SAME
US14/171,299 US9289485B2 (en) 2006-11-30 2014-02-03 Therapeutic application of S. pyogenes C-terminal peptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0604997-4A BRPI0604997A (pt) 2006-11-30 2006-11-30 vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção

Publications (1)

Publication Number Publication Date
BRPI0604997A true BRPI0604997A (pt) 2007-05-22

Family

ID=38051203

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0604997-4A BRPI0604997A (pt) 2006-11-30 2006-11-30 vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção

Country Status (7)

Country Link
US (1) US8642049B2 (pt)
EP (1) EP2099481A4 (pt)
JP (1) JP5410294B2 (pt)
KR (1) KR101511800B1 (pt)
CN (1) CN101557822B (pt)
BR (1) BRPI0604997A (pt)
WO (1) WO2008064440A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9289485B2 (en) * 2006-11-30 2016-03-22 Luiza Guilherme Guglielmi Therapeutic application of S. pyogenes C-terminal peptide
CA2838981C (en) * 2011-06-17 2020-09-08 University Of Tennessee Research Foundation Group a streptococcus multivalent vaccine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009064A1 (en) 1988-03-25 1989-10-05 The Rockefeller University Synthetic peptides from streptococcal m protein and vaccines prepared therefrom
US6602507B1 (en) * 1988-03-25 2003-08-05 The Rockefeller University Synthetic peptides from streptococcal M protein and vaccines prepared therefrom
AU5948490A (en) * 1989-06-21 1991-01-08 Rockefeller University, The Recombinant poxvirus and streptococcal m protein vaccine
EP0618813B1 (en) * 1992-09-16 2002-01-09 The University Of Tennessee Research Corporation Antigen of hybrid m protein and carrier for group a streptococcal vaccine
IL107025A0 (en) * 1992-09-16 1993-12-28 Univ Tennessee Res Corp Recombinant multivalent m protein vaccine
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US6716433B1 (en) * 1997-09-12 2004-04-06 University Of Tennessee Research Foundation Group a streptococcal vaccines
BR0313154A (pt) 2002-08-12 2005-08-02 Council The Queensland Inst Of Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
EP1601770B1 (en) 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigens
BRPI0501290A (pt) * 2005-03-24 2005-12-06 Fundacao Zerbini Vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção

Also Published As

Publication number Publication date
WO2008064440A1 (en) 2008-06-05
US20100183518A1 (en) 2010-07-22
EP2099481A1 (en) 2009-09-16
EP2099481A4 (en) 2012-12-12
CN101557822B (zh) 2013-08-14
KR101511800B1 (ko) 2015-04-28
CN101557822A (zh) 2009-10-14
JP2010510991A (ja) 2010-04-08
KR20090086454A (ko) 2009-08-12
JP5410294B2 (ja) 2014-02-05
US8642049B2 (en) 2014-02-04

Similar Documents

Publication Publication Date Title
Abdel‐Aal et al. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist
Schultz-Thater et al. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens
Mckenzie et al. Sequence and immunogenicity of the 70-kDa heat shock protein of Mycobacterium leprae
CN106413749B (zh) 新颖全谱抗登革抗体
Castro et al. Identification and characterization of B-cell epitopes of 3FTx and PLA2 toxins from Micrurus corallinus snake venom
BR0213941A (pt) Arranjos de antìgeno para o tratamento de doença óssea
Vashishtha et al. Surface-exposed conserved region of the streptococcal M protein induces antibodies cross-reactive with denatured forms of myosin
Yano et al. RGD motif enhances immunogenicity and adjuvanicity of peptide antigens following intranasal immunization
JP4313433B2 (ja) イミュノグロブリン結合能を有するペプチド
Hossain et al. The cysteine-rich regions of Plasmodium falciparum RON2 bind with host erythrocyte and AMA1 during merozoite invasion
Angeletti et al. Analysis of antibody induction upon immunization with distinct NTS-DBL1α-domains of PfEMP1 from rosetting Plasmodium falciparum parasites
US20200216516A1 (en) Fusion peptides of cd4 helper t cell epitopes and vaccines thereof
Sharafi et al. A nonglycosylated 27 kDa molecule as common antigen between human breast cancer and Echinococcus granulosus hydatid cyst wall
AU6653096A (en) Hybrid protein comprising t-helper cell stimulating epitopes and b-cell epitopes from the major outer membrane protein of chlamydia trachomatis and its use as a vaccine
JP2004501645A (ja) Ｃ末端Ｅｒｎｓペプチド中の輸送ペプチドおよびその類似体
McMillan et al. Identification and assessment of new vaccine candidates for group A streptococcal infections
Lin et al. Molecular characterization of three major outer membrane proteins, TSA56, TSA47 and TSA22, in Orientia tsutsugamushi
TWI549964B (zh) 敗血性巴氏桿菌毒素重組蛋白及其應用
US20210106677A1 (en) Vaccine development methodology based on an adhesion molecule
WO2001029198A1 (en) Polypeptide fragments comprising c-terminal portion of helicobacter catalase
CN101906163A (zh) 一种免疫避孕的合成肽和嵌合肽及其应用
US8916162B2 (en) Botulinum neurotoxin antigenic compositions and methods
Delogu et al. Impact of structural domains of the heparin binding hemagglutinin of Mycobacterium tuberculosis on function
CN102775486B (zh) 监测肾损伤的新型试剂和试剂盒
Gadzinski et al. Transfer of the ability of HIV-1 Tat to raise an adjuvant-free humoral immune response to unrelated antigens

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LUIZA GUILHERME GUGLIELMI (BR/SP) , JORGE ELIAS KA

Free format text: TRANSFERIDO DE: FUNDACAO ZERBINI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal: appeal against refusal